Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/135201ANTIBODY AND USE THEREOF
WO 02.07.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/126495 Applicant SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Inventor TIAN, Haijun
The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.
2.WO/2020/135335MULTISPECIFIC ANTIGEN BINDING PROTEINS CAPABLE OF BINDING CD19 AND CD3, AND USE THEREOF
WO 02.07.2020
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/CN2019/127433 Applicant GENERON (SHANGHAI) CORPORATION LTD. Inventor HUANG, Zhihua
Provided are multispecific antigen binding proteins (MSAPs) that specifically bind to CD3 and CD19. Further provided are uses of the MSAPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the MSAPs.
3.WO/2020/135415USE OF ANTI-PD-L1 MONOCLONAL ANTIBODY FOR TREATMENT OF CANCER
WO 02.07.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2019/127891 Applicant CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Inventor ZHANG, Xiquan
The present application provides use of an anti-PD-L1 monoclonal antibody for treatment of cancer, comprising administering to a subject a therapeutically effective amount of an inhibitor of the interaction between a PD-1 receptor and a ligand PD-L1 thereof, wherein the inhibitor is an anti-PD-L1 monoclonal antibody.
4.WO/2020/136060A PEPTIDE-MHC-I-ANTIBODY FUSION PROTEIN FOR THERAPEUTIC USE IN A PATIENT WITH AMPLIFIED IMMUNE RESPONSE
WO 02.07.2020
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2019/086072 Applicant F. HOFFMANN-LA ROCHE AG Inventor KNOETGEN, Hendrik
The present invention relates to a peptide-MHC-I-antibody fusion protein for use as a therapeutic medicament administered to a patient, wherein a cellular cytotoxic immune response towards the virus-derived peptide has been amplified in the patient. The therapeutic medicament may be used in a kit of parts and administered in combination with an amplifying medicament and optionally an inducing medicament. The inducing medicament and the amplifying medicament may be for use in a method of making a patient susceptible for a treatment with the peptide-MHC-I-antibody fusion protein.The medicament(s) may be used for the treatment of diseases, such as cancer or a viral infection.
5.WO/2020/138489NOVEL ANTI-CCR8 ANTIBODY
WO 02.07.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2019/051603 Applicant SHIONOGI & CO., LTD. Inventor KODAMA Mai
Disclosed is a novel anti-CCR8 antibody. The antibody may be used for treating or preventing cancers or the like.
6.WO/2020/135471MONOCLONAL ANTIBODY AGAINST HUMAN INTERLEUKIN-4 RECEPTOR ALPHA AND USE THEREOF
WO 02.07.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/128156 Applicant QYUNS THERAPEUTICS CO., LTD. Inventor QIU, Jiwan
Provided are antibodies and fragments against human interleukin-4 receptor alpha (hIL-4Rα) and uses thereof. The antibodies and fragments preferably have heavy chain complementary determining regions as set forth in SEQ ID NOs: 1-3 or 14-16 and light chain complementary determining regions as set forth in SEQ ID NOs: 4-6 or 17-19.
7.WO/2020/135555BIVALENT BISPECIFIC ANTIBODY AND PREPARTION METHOD THEREOF, CODING GENE, HOST CELL AND COMPOSITION
WO 02.07.2020
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/CN2019/128582 Applicant CHANGCHUN GENESCIENCE PHARMACEUTICALS CO., LTD. Inventor FENG, Xiao
Provided are a bivalent bispecific antibody and a preparation method thereof, a coding gene, a host cell and a composition. The bivalent bispecific antibody comprises: a) a single-chain variable fragment scFv, a flexible peptide, a heavy chain IgG1 constant region CH1 and a hinge region partial sequence of the antibody that specifically binds to a first antigen, and b) a single-chain variable fragment scFv, and a light chain constant region CL, that is, scFv1-CL or CL-scFv1, of the antibody that specifically binds to a second antigen; or comprises: c) a light chain and a heavy chain of the antibody that specifically binds to the first antigen, and d) a light chain and a heavy chain of the antibody that specifically binds to the second antigen.
8.WO/2020/135710ANTIBODY AGAINST HUMAN IL-4RA AND USE THEREOF
WO 02.07.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/129193 Applicant AKESO BIOPHARMA, INC Inventor LI, Baiyong
Provided is an antibody against human interleukin 4-receptor A, a pharmaceutical composition or a kit comprising thereof, and a use thereof.
9.WO/2020/136101ANTI-IL-36R ANTIBODIES FOR TREATMENT OF PALMOPLANTAR PUSTULOSIS
WO 02.07.2020
Int.Class A61P 17/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
Appl.No PCT/EP2019/086521 Applicant BOEHRINGER INGELHEIM INTERNATIONAL GMBH Inventor THOMA, Christian
The present disclosure relates to the treatment of or alleviation of signs and symptoms of palmoplantar pustulosis (PPP) with anti-IL-36R antibodies in a patient.
10.WO/2020/136879METHOD FOR PRESENTING EFFECTIVENESS OF IMMUNOTHERAPEUTIC AGENT FOR TREATING MALIGNANT TUMOR AND IMMUNOTHERAPEUTIC AGENT FOR TREATING MALIGNANT TUMOR
WO 02.07.2020
Int.Class C12Q 1/18
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
18Testing for antimicrobial activity of a material
Appl.No PCT/JP2018/048494 Applicant OSAKA UNIVERSITY Inventor IWAHORI, Kota
The present invention addresses the problem of presenting information required in companion diagnostics for predicting the effectiveness of an immunotherapeutic agent for individual patients. To solve the problem, the present invention provides a method for presenting the effectiveness of an immunotherapeutic agent for treating a malignant tumor for a patient having a malignant tumor, the method including the following steps 1 and 2. Step 1: a step for assessing whether tumor cells are damaged after directly or indirectly contacting, in vitro, peripheral blood mononuclear cells collected from the patient. Step 2: a step for presenting that the immunotherapeutic agent is effective for the patient if the assessment indicates that the tumor cells are damaged, and/or a step for presenting that the immunotherapeutic agent is not effective for the patient if the assessment indicates that the tumor cells are not damaged.